Literature DB >> 7545684

Suramin inhibits C6 glioma-induced angiogenesis in vitro.

B L Coomber1.   

Abstract

Aspects of tumor-induced angiogenesis in vitro were examined using an assay involving collagen gel invasion by a surface monolayer of bovine endothelial cells under the influence of serum free conditioned medium produced by C6 cells, an experimentally derived rat glial tumor cell line. The effects of the polyanionic compound suramin, known to interfere with growth factor/cell signaling on this process were evaluated. Collagen gel invasion was quantified by adding C6 conditioned medium with or without various doses of suramin to monolayers of bovine aortic endothelial cells grown on type I collagen gels in transwell inserts. Cultures were monitored with phase-contrast microscopy. After various periods of incubation collagen gels were fixed, embedded in epoxy resin, and 1-micron thick sections were stained with toluidine blue. Additional cultures were used to evaluate the effects of C6 conditioned medium and suramin on endothelial cell proliferation, and on chemotaxis through 8-microns pores. C6 glioma cell conditioned medium induced large vessel endothelial cells to sprout into the underlying collagen matrix and subsequently form networks of capillary like tubes. Conditioned medium was also chemotactic and mitogenic for these cells. The addition of suramin to C6 glioma conditioned medium prevents tube formation in collagen gels, and inhibits both endothelial cell proliferation and chemotaxis in a dose dependent manner. These results suggest that glial tumor cell conditioned medium induces angiogenesis in large vessel endothelial cells in vitro via mechanisms which are disrupted by suramin, most likely involving tumor-derived growth factor release and/or endothelium-mediated matrix proteolysis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545684     DOI: 10.1002/jcb.240580209

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  9 in total

1.  In vivo engineering of organs: the bone bioreactor.

Authors:  Molly M Stevens; Robert P Marini; Dirk Schaefer; Joshua Aronson; Robert Langer; V Prasad Shastri
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-29       Impact factor: 11.205

Review 2.  Platelet-derived growth factor in human brain tumors.

Authors:  M Kirsch; J C Wilson; P Black
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

Review 3.  Anti-angiogenic treatment strategies for malignant brain tumors.

Authors:  M Kirsch; G Schackert; P M Black
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

4.  Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status.

Authors:  H J Bernsen; P F Rijken; J P Peters; J H Bakker; R H Boerman; P Wesseling; A J van der Kogel
Journal:  J Neurooncol       Date:  1999-09       Impact factor: 4.130

Review 5.  Antiangiogenic therapy in brain tumor models.

Authors:  H J Bernsen; A J van der Kogel
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

6.  The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.

Authors:  Una Adamcic; Karolina Skowronski; Craig Peters; Jodi Morrison; Brenda L Coomber
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

7.  Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study.

Authors:  John J Laterra; Stuart A Grossman; Kathryn A Carson; Glenn J Lesser; Fred H Hochberg; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

8.  Release of endothelial cell associated VEGFR2 during TGF-β modulated angiogenesis in vitro.

Authors:  M Jarad; E A Kuczynski; J Morrison; A M Viloria-Petit; B L Coomber
Journal:  BMC Cell Biol       Date:  2017-01-23       Impact factor: 4.241

9.  Differential expression of Tie2 receptor and VEGFR2 by endothelial clones derived from isolated bovine mononuclear cells.

Authors:  Una Adamcic; Alexander Yurkiewich; Brenda L Coomber
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.